Association of hydrophilic versus lipophilic angiotensin-converting enzyme inhibitor use on pneumonia-related mortality

Eric M. Mortensen, Marcos I. Restrepo, Laurel A. Copeland, Jacqueline A. Pugh, Antonio Anzueto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND: Recent studies suggest that angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for patients with or at risk for pneumonia. However, other studies have not found a survival benefit. Other research suggests that ACE inhibitors that are lipophilic may be superior to hydrophilic ACE inhibitors in terms of tissue penetration and inhibition of ACE. Our aim was to examine the associations of prior outpatient use of lipophilic and hydrophilic ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia. METHODS: A retrospective cohort study of subjects hospitalized with pneumonia at 2 tertiary teaching hospitals. We examined whether the prior outpatient use of hydrophilic or lipophilic ACE inhibitors was associated with 30-day mortality in a logistic regression analysis that adjusted for potential confounders using a propensity score. RESULTS: Data were abstracted on 787 subjects at the 2 hospitals. In our cohort, 24% (n = 186) were on ACE inhibitors at presentation: 111 lipophilic and 74 hydrophilic. Mortality was 9.2% at 30 days. In the multivariable model, lipophilic ACE inhibitor use (odds ratio 0.3, 95% confidence interval 0.1-0.8), but not hydrophilic ACE inhibitor use (0.7, 0.3-1.7), was significantly associated with 30-day mortality. CONCLUSIONS: Our study suggests that future research of ACE inhibitors in pneumonia must describe the specific medications received. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.

Original languageEnglish (US)
Pages (from-to)462-466
Number of pages5
JournalAmerican Journal of the Medical Sciences
Volume336
Issue number6
DOIs
StatePublished - Dec 2008

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Pneumonia
Mortality
Outpatients
Propensity Score
Peptidyl-Dipeptidase A
Research
Tertiary Care Centers
Teaching Hospitals
Cohort Studies
Retrospective Studies
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals
Survival

Keywords

  • Angiotensin-converting enzyme
  • Mortality
  • Pneumonia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Association of hydrophilic versus lipophilic angiotensin-converting enzyme inhibitor use on pneumonia-related mortality. / Mortensen, Eric M.; Restrepo, Marcos I.; Copeland, Laurel A.; Pugh, Jacqueline A.; Anzueto, Antonio.

In: American Journal of the Medical Sciences, Vol. 336, No. 6, 12.2008, p. 462-466.

Research output: Contribution to journalArticle

Mortensen, Eric M. ; Restrepo, Marcos I. ; Copeland, Laurel A. ; Pugh, Jacqueline A. ; Anzueto, Antonio. / Association of hydrophilic versus lipophilic angiotensin-converting enzyme inhibitor use on pneumonia-related mortality. In: American Journal of the Medical Sciences. 2008 ; Vol. 336, No. 6. pp. 462-466.
@article{8adb81ae36d647d2a992ed30cfa96935,
title = "Association of hydrophilic versus lipophilic angiotensin-converting enzyme inhibitor use on pneumonia-related mortality",
abstract = "BACKGROUND: Recent studies suggest that angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for patients with or at risk for pneumonia. However, other studies have not found a survival benefit. Other research suggests that ACE inhibitors that are lipophilic may be superior to hydrophilic ACE inhibitors in terms of tissue penetration and inhibition of ACE. Our aim was to examine the associations of prior outpatient use of lipophilic and hydrophilic ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia. METHODS: A retrospective cohort study of subjects hospitalized with pneumonia at 2 tertiary teaching hospitals. We examined whether the prior outpatient use of hydrophilic or lipophilic ACE inhibitors was associated with 30-day mortality in a logistic regression analysis that adjusted for potential confounders using a propensity score. RESULTS: Data were abstracted on 787 subjects at the 2 hospitals. In our cohort, 24{\%} (n = 186) were on ACE inhibitors at presentation: 111 lipophilic and 74 hydrophilic. Mortality was 9.2{\%} at 30 days. In the multivariable model, lipophilic ACE inhibitor use (odds ratio 0.3, 95{\%} confidence interval 0.1-0.8), but not hydrophilic ACE inhibitor use (0.7, 0.3-1.7), was significantly associated with 30-day mortality. CONCLUSIONS: Our study suggests that future research of ACE inhibitors in pneumonia must describe the specific medications received. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.",
keywords = "Angiotensin-converting enzyme, Mortality, Pneumonia",
author = "Mortensen, {Eric M.} and Restrepo, {Marcos I.} and Copeland, {Laurel A.} and Pugh, {Jacqueline A.} and Antonio Anzueto",
year = "2008",
month = "12",
doi = "10.1097/MAJ.0b013e31817149ed",
language = "English (US)",
volume = "336",
pages = "462--466",
journal = "The American journal of the medical sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Association of hydrophilic versus lipophilic angiotensin-converting enzyme inhibitor use on pneumonia-related mortality

AU - Mortensen, Eric M.

AU - Restrepo, Marcos I.

AU - Copeland, Laurel A.

AU - Pugh, Jacqueline A.

AU - Anzueto, Antonio

PY - 2008/12

Y1 - 2008/12

N2 - BACKGROUND: Recent studies suggest that angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for patients with or at risk for pneumonia. However, other studies have not found a survival benefit. Other research suggests that ACE inhibitors that are lipophilic may be superior to hydrophilic ACE inhibitors in terms of tissue penetration and inhibition of ACE. Our aim was to examine the associations of prior outpatient use of lipophilic and hydrophilic ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia. METHODS: A retrospective cohort study of subjects hospitalized with pneumonia at 2 tertiary teaching hospitals. We examined whether the prior outpatient use of hydrophilic or lipophilic ACE inhibitors was associated with 30-day mortality in a logistic regression analysis that adjusted for potential confounders using a propensity score. RESULTS: Data were abstracted on 787 subjects at the 2 hospitals. In our cohort, 24% (n = 186) were on ACE inhibitors at presentation: 111 lipophilic and 74 hydrophilic. Mortality was 9.2% at 30 days. In the multivariable model, lipophilic ACE inhibitor use (odds ratio 0.3, 95% confidence interval 0.1-0.8), but not hydrophilic ACE inhibitor use (0.7, 0.3-1.7), was significantly associated with 30-day mortality. CONCLUSIONS: Our study suggests that future research of ACE inhibitors in pneumonia must describe the specific medications received. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.

AB - BACKGROUND: Recent studies suggest that angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for patients with or at risk for pneumonia. However, other studies have not found a survival benefit. Other research suggests that ACE inhibitors that are lipophilic may be superior to hydrophilic ACE inhibitors in terms of tissue penetration and inhibition of ACE. Our aim was to examine the associations of prior outpatient use of lipophilic and hydrophilic ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia. METHODS: A retrospective cohort study of subjects hospitalized with pneumonia at 2 tertiary teaching hospitals. We examined whether the prior outpatient use of hydrophilic or lipophilic ACE inhibitors was associated with 30-day mortality in a logistic regression analysis that adjusted for potential confounders using a propensity score. RESULTS: Data were abstracted on 787 subjects at the 2 hospitals. In our cohort, 24% (n = 186) were on ACE inhibitors at presentation: 111 lipophilic and 74 hydrophilic. Mortality was 9.2% at 30 days. In the multivariable model, lipophilic ACE inhibitor use (odds ratio 0.3, 95% confidence interval 0.1-0.8), but not hydrophilic ACE inhibitor use (0.7, 0.3-1.7), was significantly associated with 30-day mortality. CONCLUSIONS: Our study suggests that future research of ACE inhibitors in pneumonia must describe the specific medications received. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.

KW - Angiotensin-converting enzyme

KW - Mortality

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=59049087675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59049087675&partnerID=8YFLogxK

U2 - 10.1097/MAJ.0b013e31817149ed

DO - 10.1097/MAJ.0b013e31817149ed

M3 - Article

C2 - 19092318

AN - SCOPUS:59049087675

VL - 336

SP - 462

EP - 466

JO - The American journal of the medical sciences

JF - The American journal of the medical sciences

SN - 0002-9629

IS - 6

ER -